Moving forwards: noninvasive imaging of the eye

Article

US pachymetry offers no advantage over optical noncontact methods, according to Dr Savini

"I believe that ultrasound (US) pachymetry does not offer any advantage over optical noncontact methods such as Scheimpflug imaging," stressed Dr Giacomo Savini (GB Bietti Eye Foundation IRCCS, Rome, Italy) when discussing a recent investigation on the precision of a new Scheimpflug and Placidodisk analyser.1 "My group has investigated all currently available Scheimpflug cameras over the last five years. Our aim has been to understand what do these instruments really measure and calculate and how can the provided values be applied in the clinical setting."

Recently, Dr Savini revealed that he had started collaborating with the School of Optometry and Ophthalmology and Eye Hospital of the Wenzhou Medical College (Wenzhou, Zhejiang, China), where a group of researchers have similar interests and founded the Institute for Assessment and Application of Ophthalmic and Optometric Instruments (IAAO).

"Together we planned to evaluate the features of several ophthalmic devices, one of which was the Sirius (CSO, Florence, Italy), a Scheimpflug camera combined with a Placido disk topographer," he continued. "Given the utmost importance of thinnest corneal thickness (TCT) measurements in patients undergoing refractive surgery, we wanted to test the reliability of the Sirius TCT measurements and assess agreement with ultrasound pachymetry, which may still be considered as the gold standard."

To assess the precision of this new instrument the team employed the same methodology as previous studies, according to the definitions adopted by the International Organization for Standardization. Healthy subjects were examined with the ScheimpflugPlacido topographer and the central corneal thickness (CCT) and thinnest corneal thickness (TCT) were recorded after three consecutive measurements.

"We had to repeat measurements three times with one operator to calculate the intraoperator repeatability and three more times within one week to calculate the intersession reproducibility," said Dr Savini. "In the second part of the study we compared the Scheimpflug measurements to those achieved by standard ultrasound pachymetry. So, the protocol was not complicated and we had no difficulties."

High repeatability

The team found that there was high intrasession and intersession repeatability for the ScheimpflugPlacido measurements. "Achieving the same value in different measurements taken on the same day or in different sessions confirms the high precision of this rotating Scheimpflug camera combined with a Placido disk topographer," said Dr Savini. "This finding makes me confident on the measured values of TCT when screening candidates for refractive surgery and increases the safety of both LASIK and PRK."

Additionally, there was a high level of agreement between the combined Scheimpflug-Placido instrument and US pachymetry measurements. Dr Savini continued, "Actually, I did not expect such a good level of agreement between Scheimpflug and ultrasound measurements. This finding makes me even more confident about the fact that I routinely use Scheimpflug measurements to assess preoperative corneal thickness in patients undergoing LASIK and PRK."

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.